Acceptable sources include:(Society guidelines (AAFP, USPSTF; website links must be provided)
https://www.aafp.org/pubs/afp/issues/2020/0201/p168.html
I check this website however it shows the 2017 IDSA guideline. There's is 2021 IDSA guideline as per uptodate
https://www.uptodate.com/contents/clostridioides-difficile-infection-in-adults-treatment-and-prevention
https://www.idsociety.org/practice-guideline/clostridioides-difficile-2021-focused-update
1. For patients with an initial CDI episode, we suggest using fidaxomicin rather than a standard course of vancomycin (conditional recommendation, moderate certainty of evidence). Comment: This recommendation places a high value in the beneficial effects and safety of fidaxomicin, but its implementation depends upon available resources. Vancomycin remains an acceptable alternative
I. In patients with recurrent CDI episodes, we suggest fidaxomicin (standard or extended-pulsed regimen) rather than a standard course of vancomycin (conditional recommendation, low certainty evidence)








Watch Macrolides




Watch Clostridioides difficile




.jpg)
.jpg)
Watch associated Bootcamp video - Antibiotics: Glycopeptides (including Vancomycin)
Watch associated Bootcamp video - Antibiotics: Empiric Antibiotics in GI, Skin, Bone, and Hematogenous Infections
Watch associated Bootcamp video - Antibiotics: Aminopenicillins